From oncogene to network addiction

The new frontier of cancer genomics and therapeutics

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recent advances in genomic analysis have provided a comprehensive view of the genetic and epigenetic changes present in cancer cells. While therapies targeting genes causally linked to carcinogenesis have been successful in a subset of tumor types, the hope for treatments tailored on patient genomic profiles seems, for most cancers, still elusive. Cancer genes belong to two clearly defined groups. The first subset of genes is frequently mutated across samples and tumor types, and includes well-studied oncogenes and tumor suppressor genes, such as members of the RAS, AKT and TP53 families, whose direct targeting has so far been largely disappointing. In the other group, the vast majority of putative cancer genes emerging from sequencing and genomic studies show a low incidence (5% or less). The possibility of finding novel selective drugs against such a high number of gene products seems daunting. However, recent genomic and proteomic findings, as well as novel frameworks arising from systems biology approaches, suggest that this apparent discordance may converge towards a more satisfying model. It seems that genetic lesions in cancer tend to cluster around certain pathways, suggesting that the concept of 'network addiction', rather than 'oncogene addiction', would recapitulate more closely what is happening during tumor development and after exposure to therapeutic agents. This new perspective, arising from genomic and systems biology studies, will likely provide a valuable frame for the design of the cancer drugs of the future.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalFuture Oncology
Volume4
Issue number4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Genomics
Oncogenes
Neoplasms
Systems Biology
Neoplasm Genes
Therapeutics
Hope
Gene Targeting
Drug Design
Tumor Suppressor Genes
Epigenomics
Genetic Therapy
Proteomics
Genes
Carcinogenesis
Incidence
Pharmaceutical Preparations

Keywords

  • aCCH
  • Array comparative genomic hybridization
  • Gene mutation
  • Genomic
  • Scale-free networks
  • Sequencing
  • Synthetic lethality
  • System biology
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

From oncogene to network addiction : The new frontier of cancer genomics and therapeutics. / Tonon, Giovanni.

In: Future Oncology, Vol. 4, No. 4, 08.2008, p. 569-577.

Research output: Contribution to journalArticle

@article{bdcf77c119e24f6c9cfa66a8d05013a8,
title = "From oncogene to network addiction: The new frontier of cancer genomics and therapeutics",
abstract = "Recent advances in genomic analysis have provided a comprehensive view of the genetic and epigenetic changes present in cancer cells. While therapies targeting genes causally linked to carcinogenesis have been successful in a subset of tumor types, the hope for treatments tailored on patient genomic profiles seems, for most cancers, still elusive. Cancer genes belong to two clearly defined groups. The first subset of genes is frequently mutated across samples and tumor types, and includes well-studied oncogenes and tumor suppressor genes, such as members of the RAS, AKT and TP53 families, whose direct targeting has so far been largely disappointing. In the other group, the vast majority of putative cancer genes emerging from sequencing and genomic studies show a low incidence (5{\%} or less). The possibility of finding novel selective drugs against such a high number of gene products seems daunting. However, recent genomic and proteomic findings, as well as novel frameworks arising from systems biology approaches, suggest that this apparent discordance may converge towards a more satisfying model. It seems that genetic lesions in cancer tend to cluster around certain pathways, suggesting that the concept of 'network addiction', rather than 'oncogene addiction', would recapitulate more closely what is happening during tumor development and after exposure to therapeutic agents. This new perspective, arising from genomic and systems biology studies, will likely provide a valuable frame for the design of the cancer drugs of the future.",
keywords = "aCCH, Array comparative genomic hybridization, Gene mutation, Genomic, Scale-free networks, Sequencing, Synthetic lethality, System biology, Targeted therapy",
author = "Giovanni Tonon",
year = "2008",
month = "8",
doi = "10.2217/14796694.4.4.569",
language = "English",
volume = "4",
pages = "569--577",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - From oncogene to network addiction

T2 - The new frontier of cancer genomics and therapeutics

AU - Tonon, Giovanni

PY - 2008/8

Y1 - 2008/8

N2 - Recent advances in genomic analysis have provided a comprehensive view of the genetic and epigenetic changes present in cancer cells. While therapies targeting genes causally linked to carcinogenesis have been successful in a subset of tumor types, the hope for treatments tailored on patient genomic profiles seems, for most cancers, still elusive. Cancer genes belong to two clearly defined groups. The first subset of genes is frequently mutated across samples and tumor types, and includes well-studied oncogenes and tumor suppressor genes, such as members of the RAS, AKT and TP53 families, whose direct targeting has so far been largely disappointing. In the other group, the vast majority of putative cancer genes emerging from sequencing and genomic studies show a low incidence (5% or less). The possibility of finding novel selective drugs against such a high number of gene products seems daunting. However, recent genomic and proteomic findings, as well as novel frameworks arising from systems biology approaches, suggest that this apparent discordance may converge towards a more satisfying model. It seems that genetic lesions in cancer tend to cluster around certain pathways, suggesting that the concept of 'network addiction', rather than 'oncogene addiction', would recapitulate more closely what is happening during tumor development and after exposure to therapeutic agents. This new perspective, arising from genomic and systems biology studies, will likely provide a valuable frame for the design of the cancer drugs of the future.

AB - Recent advances in genomic analysis have provided a comprehensive view of the genetic and epigenetic changes present in cancer cells. While therapies targeting genes causally linked to carcinogenesis have been successful in a subset of tumor types, the hope for treatments tailored on patient genomic profiles seems, for most cancers, still elusive. Cancer genes belong to two clearly defined groups. The first subset of genes is frequently mutated across samples and tumor types, and includes well-studied oncogenes and tumor suppressor genes, such as members of the RAS, AKT and TP53 families, whose direct targeting has so far been largely disappointing. In the other group, the vast majority of putative cancer genes emerging from sequencing and genomic studies show a low incidence (5% or less). The possibility of finding novel selective drugs against such a high number of gene products seems daunting. However, recent genomic and proteomic findings, as well as novel frameworks arising from systems biology approaches, suggest that this apparent discordance may converge towards a more satisfying model. It seems that genetic lesions in cancer tend to cluster around certain pathways, suggesting that the concept of 'network addiction', rather than 'oncogene addiction', would recapitulate more closely what is happening during tumor development and after exposure to therapeutic agents. This new perspective, arising from genomic and systems biology studies, will likely provide a valuable frame for the design of the cancer drugs of the future.

KW - aCCH

KW - Array comparative genomic hybridization

KW - Gene mutation

KW - Genomic

KW - Scale-free networks

KW - Sequencing

KW - Synthetic lethality

KW - System biology

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=55349137715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349137715&partnerID=8YFLogxK

U2 - 10.2217/14796694.4.4.569

DO - 10.2217/14796694.4.4.569

M3 - Article

VL - 4

SP - 569

EP - 577

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -